Helixgate https://validator.w3.org/feed/docs/rss2.html CVS’ healthcare delivery chief eyes potential in clinical AI Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth Bioprocessing Applications Laboratory Opened in Korea by Ecolab Life Sciences Smog from wildfires increasingly harmful, data show Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study Lack of specifics on obesity pill sales hover over Lilly’s first quarter Novartis unveils North Carolina factory as final new build in $23B US expansion STAT+: What does Akeso’s primo plenary spot say about its survival data? STAT+: New obesity tool aims to predict risk of 18 serious complications What makes life science angel investment work? 6 biotechs that called it quits in Q1 7 companies hiring in North Carolina now Tackling drug resistance must become biotech’s next frontier FDA’s end to 9-month adcomm drought a ‘narrow restart’ Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M Avalyn, in pursuit of better lung drugs, banks $300M in an IPO Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier STAT+: Supreme Court justices appear to signal ‘skinny labeling’ can survive HHS appeals ruling that stalled many of Kennedy’s vaccine policy changes AbbVie faces questions about Skyrizi competition from J&J AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate “Click Clotting” Technique Rapidly Creates Stronger Blood Clots STAT+: Why conversations around health AI may be evolving beyond hype Supply Chain Digital Twins: An Evolution, Not a Breakthrough Teva nabs experimental Tourette drug in $700M Emalex buyout Loss of Smell Therapies Informed by Olfactory Receptor Spatial Mapping Chiesi to buy KalVista in $1.9B deal for rare disease drug Bristol Myers reaches a crossroads as a make-or-break year takes shape With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’ Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings Meet the Researcher: Fred Ramsdell, Nobel winner  Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla FDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient death Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly A patent win for Pfizer and BridgeBio Chiesi signs $1.9B deal to acquire KalVista and its approved drug AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins GSK’s Shingrix strategy shift drives sales beat even as vaccines slow Pfizer settles with generic drugmakers to protect blockbuster drug until 2031 Food safety experts warn of USDA brain drain AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readouts STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions Hepatocyte Detargeting Improves mRNA Vaccine Immunity in Lymphoma Model Opinion: The medical school nutrition blues Opinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides? Home